#OptiTROP - Twitter Hashtag

5 months ago

🔥🚨@OncoAlert Hot off the press. Just published @TheLancet in conjunction with presentation @ASCO #ASCO26 ⭐️Interim Analysis of phase 3 trial; #OptiTROP-#Lung05 of: ❇️#Sacituzumab Tirumotecan (Sac-TMT)+ #Pembrolizumab Vs #Pembrolizumab in #PDL1+ advanced non-small-cell #LungCancer. ✅#mPFS (Not reached) vs 5.7m (HR 0.35) ✅#ORR 70.2% vs 42.0% ✅Immature #OS data; Positive trend (HR 0.55) 🔴 ≥ Grade 3 Tx emergent #AEs: 55% vs 31% 👇🏻 https://t.co/OZWx44hNtU

RManochakian's tweet photo. 🔥🚨@OncoAlert Hot off the press.

Just published @TheLancet in conjunction with presentation @ASCO #ASCO26

⭐️Interim Analysis of phase 3 trial;
#OptiTROP-#Lung05 of:

❇️#Sacituzumab Tirumotecan (Sac-TMT)+ #Pembrolizumab Vs #Pembrolizumab in #PDL1+ advanced non-small-cell #LungCancer.

✅#mPFS (Not reached) vs 5.7m (HR 0.35)
✅#ORR 70.2% vs 42.0%
✅Immature #OS data; Positive trend
(HR 0.55)
🔴 ≥ Grade 3 Tx emergent #AEs:
55% vs 31%

👇🏻
https://t.co/OZWx44hNtU

4

34

16

3

2K

Chul Kim

@chulkimMD

5 months ago

#OptiTROP-Lung05 met its primary endpoint: sac-TMT + pembrolizumab improved PFS vs pembrolizumab alone in 1L PD-L1+ advanced NSCLC (HR 0.35). Benefit was seen across PD-L1 subgroups (more pronounced in PD-L1 1-49% vs. >=50%), with an early OS signal (HR 0.55). #ASCO26

chulkimMD's tweet photo. #OptiTROP-Lung05 met its primary endpoint: sac-TMT + pembrolizumab improved PFS vs pembrolizumab alone in 1L PD-L1+ advanced NSCLC (HR 0.35). Benefit was seen across PD-L1 subgroups (more pronounced in PD-L1 1-49% vs. >=50%), with an early OS signal (HR 0.55). #ASCO26 https://t.co/0TrKnO2eoW

1

17

3

997

Dr Mathew Wilson @MathewGWilson

12 months ago

#HARMONi-6 & #OptiTROP-Lung04 both large phase3 RCT in a china🇨🇳 only population. Both given Presidentials #ESMO25 Question raised re confirmatory trials in worldwide setting. Is this necessary in 2025? Why don’t we raise this question to EU/US trials?🇪🇺🇺🇸 #oncology #LCSM

0

2

1

0

187

Diego A. Díaz-García

@diegoadiazg

12 months ago

🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04 The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD. Could this redefine post-TKI therapy sequencing? Will this become a global standard too? #CánCare #NSCLC #lcsm #TROP2 #ADC #EGFR #ESMO25

diegoadiazg's tweet photo. 🫁 Sacituzumab-tmt: A new SoC for EGFR-TKI–resistant NSCLC? #OptiTROP-Lung04

The first TROP2 ADC to show significant PFS and OS benefits vs platinum chemo, with fewer serious AEs (7.4% vs 17%) and no ILD.
Could this redefine post-TKI therapy sequencing? Will this become a global standard too?

#CánCare #NSCLC #lcsm #TROP2 #ADC #EGFR #ESMO25

1

12

3

12

1K

Dr Mathew Wilson @MathewGWilson

12 months ago

#OptiTROP-Lung04 🫁Sac-TMT (Trop2 ADC) vs Pt doublet in EGFR mutant #NSCLC 2nd line after targeted therapy mPFS 8.3 vs 4.3months mOS Not Reached vs 17.4months No ILD/pneumonitis. G3 Tox similar in both arms Exciting option, in a challenging setting #ESMO25 @OncoAlert #LCSM

MathewGWilson's tweet photo. #OptiTROP-Lung04

🫁Sac-TMT (Trop2 ADC) vs Pt doublet in EGFR mutant #NSCLC 2nd line after targeted therapy

mPFS 8.3 vs 4.3months
mOS Not Reached vs 17.4months

No ILD/pneumonitis. G3 Tox similar in both arms

Exciting option, in a challenging setting

#ESMO25 @OncoAlert #LCSM https://t.co/3yEhkdmBS1

1

9

5

0

740

Rami Manochakian MD, FASCO

@RManochakian

12 months ago

🔥🚨@OncoAlert Hot Off The Press. Just published @NEJM in conjunction with presentation @myESMO #ESMO25 Results of: 🎯#OptiTROP-Lung04 phase 3 trial of: ⭐️#Sacituzumab tirumotecan (#TROP2 #ADC) VS #Chemotherapy in advanced #EGFR mutant non-small cell #LungCancer after progression on #TKI ✅Statistically Significant Improvement in: ⬆️ #OverallSurvival (#OS) & ⬆️#ProgressionFreeSurvival (#PFS) 👇🏻 https://t.co/h6947b8bjL

RManochakian's tweet photo. 🔥🚨@OncoAlert Hot Off The Press.

Just published @NEJM in conjunction with presentation @myESMO #ESMO25

Results of:

🎯#OptiTROP-Lung04 phase 3 trial of:

⭐️#Sacituzumab tirumotecan (#TROP2 #ADC) VS #Chemotherapy in advanced #EGFR mutant non-small cell #LungCancer after progression on #TKI

✅Statistically Significant Improvement in:
⬆️ #OverallSurvival (#OS) &
⬆️#ProgressionFreeSurvival (#PFS)

👇🏻
https://t.co/h6947b8bjL

2

59

19

5

4K

Dr. Estela Rodriguez

@Latinamd

over 1 year ago

#ASCO25: Oral Abs 8507 #OptiTROP-Lung03 study #Sacituzumab tirumotecan sac-TMT) in previously treated #EGFR+🫁 vs docetaxel 🎙️Dr Ali Zhang 🔹N=137 🔹ORR 45% vs 15% 🔹mPFS 6.9 vs 2.8 ⬆️ AEs- cytopenias, stomatitis, neuropathy ➡️ Based on experience of other TROP2 ADCs unclear if this benefit will hold #lcsm

Latinamd's tweet photo. #ASCO25: Oral Abs 8507
#OptiTROP-Lung03 study

#Sacituzumab tirumotecan sac-TMT) in previously treated #EGFR+🫁 vs docetaxel

🎙️Dr Ali Zhang
🔹N=137
🔹ORR 45% vs 15%
🔹mPFS 6.9 vs 2.8
⬆️ AEs- cytopenias, stomatitis, neuropathy

➡️ Based on experience of other TROP2 ADCs unclear if this benefit will hold
#lcsm

0

5

0

388

Decera Clinical Education

@DeceraClinEdu

over 2 years ago

@NarjustFlorezMD @Florez_Lab @LatinasInMed @LUNGevity @ABOHLung @lcrf_org @YoungLungCancer @COlazagasti @SraVelazquezOHS @benmlevy @lungsforliving @LungAssociation @lungoncdoc @shrutis_patel @icareforlungs @GO2forLungCancr @EGFRResisters @IASLC @Sam_Kaufman @AnaVManana @ALKPositiveAUS The phase II #OptiTROP-Lung01 trial studied sacituzumab tirumotecan in combination with the PD-L1 inhibitor KL-A167; responses are promising.

DeceraClinEdu's tweet photo. @NarjustFlorezMD @Florez_Lab @LatinasInMed @LUNGevity @ABOHLung @lcrf_org @YoungLungCancer @COlazagasti @SraVelazquezOHS @benmlevy @lungsforliving @LungAssociation @lungoncdoc @shrutis_patel @icareforlungs @GO2forLungCancr @EGFRResisters @IASLC @Sam_Kaufman @AnaVManana @ALKPositiveAUS The phase II #OptiTROP-Lung01 trial studied sacituzumab tirumotecan in combination with the PD-L1 inhibitor KL-A167; responses are promising. https://t.co/8WkoFRm77o

1

4

0

369

Jennifer A. Marks, MD @jennifermarksmd

over 2 years ago

#Sac-TMT+KL-A167 in #OptiTROP-Lung01 as 1L #NSCLC may be beneficial in sq-NSCLC. Paper toxicities mostly but ORRs seem promising. Only time will tell if #ADC plus KL-A167 will be superior in this setting. #lcsm #asco24

jennifermarksmd's tweet photo. #Sac-TMT+KL-A167 in #OptiTROP-Lung01 as 1L #NSCLC may be beneficial in sq-NSCLC. Paper toxicities mostly but ORRs seem promising. Only time will tell if #ADC plus KL-A167 will be superior in this setting. #lcsm #asco24 https://t.co/qlKnetgBIg

0

2

1

0

530

Paolo Tarantino

@PTarantinoMD

over 2 years ago

@ADesaiMD @LungCancerRx @RManochakian @JackWestMD @lungoncdoc @FawziAbuRous @DevikaDasMD #lcsm may have the plenaries, but #bcsm has 🔥 hot new ADCs! For abstract no.5️⃣, I OPT for #OptiTROP-Breast01. SKB264 is a new Trop2 ADC with promising ph1 data and multiple ongoing ph3 trials. OptiTROP-B01 is the first ph 3 trial for TNBC. Excited to see the results at #ASCO24!

PTarantinoMD's tweet photo. @ADesaiMD @LungCancerRx @RManochakian @JackWestMD @lungoncdoc @FawziAbuRous @DevikaDasMD #lcsm may have the plenaries, but #bcsm has 🔥 hot new ADCs!

For abstract no.5️⃣, I OPT for #OptiTROP-Breast01. SKB264 is a new Trop2 ADC with promising ph1 data and multiple ongoing ph3 trials. OptiTROP-B01 is the first ph 3 trial for TNBC. Excited to see the results at #ASCO24! https://t.co/V3mWxjmulx

3

8

3

2

1K

Top Tweets for #OptiTROP

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users